Hematologic Malignancy
B-Cell Non-Hodgkin Lymphoma
CI-CAN-00000471Explore in graph →
Hematologic1,757 active trials43 approved drugs73 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000471Explore in graph →
Clinical trials
6,181 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (954)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00600353 | Multi-day Doses in Prevention of Nausea and Emesis | completed | Phase 2 | 20 | University of Kansas Medical CenterOTHER | 1 | Mar 9, 2017 | clinicaltrials |
| NCT01181271 | Tandem Auto-Allo Transplant for Lymphoma | completed | Phase 2 | 42 | Massachusetts General HospitalOTHER | 1 | Mar 9, 2017 | clinicaltrials |
| NCT00143845 |
| Study of Low-Intensity Conditioning for Allogeneic Stem Cell Transplant |
| completed |
| Phase 2 |
| 54 |
| University of Michigan Rogel Cancer CenterOTHER |
| 1 |
| Mar 8, 2017 |
| clinicaltrials |
| NCT00408681 | Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant(GVHD) | completed | N/A | 20 | Fred Hutchinson Cancer CenterOTHER | 1 | Mar 7, 2017 | clinicaltrials |
| NCT00307086 | Bortezomib Followed by High-Dose Melphalan and Bortezomib as Conditioning Regimen for Tandem Stem Cell Transplants | completed | Phase 2 | 30 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 6, 2017 | clinicaltrials |
| NCT00361140 | Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT) | completed | Phase 4 | 72 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 3, 2017 | clinicaltrials |
| NCT03069248 | Treatment of Follicular Lymphoma With High Dose Therapy and Stem Cell Support Followed by Rituximab and Alpha Interferon | completed | Phase 2 | 36 | Sunnybrook Health Sciences CentreOTHER | 1 | Mar 3, 2017 | clinicaltrials |
| NCT01809600 | Retrospective Analysis of Rituximab-containing Immunochemotherapy for Burkitt's or Burkitt-like Lymphoma in Adults(RBL) | completed | — | 43 | Gachon University Gil Medical CenterOTHER | 1 | Feb 24, 2017 | clinicaltrials |
| NCT02401295 | ATRA, Celecoxib, and Itraconazole as Maintenance | completed | Phase 1 | 1 | University of IowaOTHER | 1 | Feb 23, 2017 | clinicaltrials |
| NCT00091260 | CC-5013 With or Without Dexamethasone in Treating Patients With Primary Systemic Amyloidosis | completed | Phase 2 | 82 | Vaishali SanchorawalaOTHER | 1 | Feb 20, 2017 | clinicaltrials |
| NCT00679367 | Melphalan, Lenalidomide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis(MRD) | completed | Phase 2 | 16 | Boston Medical CenterOTHER | 1 | Feb 20, 2017 | clinicaltrials |
| NCT01019174 | Lenalidomide/Low-dose Dexamethasone in Combination With Continuous Oral Cyclophosphamide Compared to Lenalidomide/Low-dose Dexamethasone Combined With Single Cyclophosphamide Doses IV in Patients With Relapsed/Refractory Multiple Myeloma(MM_LEN_DEX_CY) | completed | Phase 1 / Phase 2 | 40 | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbHOTHER | 1 | Feb 20, 2017 | clinicaltrials |
| NCT00193973 | Idarubicin Based Combined Modality Therapy in Primary CNS Lymphoma | completed | Phase 2 | 20 | Trans Tasman Radiation Oncology GroupOTHER | 2 | Feb 17, 2017 | clinicaltrials |
| NCT01910987 | Study to Evaluate Optimized Retreatment and Prolonged Therapy With Bortezomib(OPTIMRETREAT) | completed | Phase 3 | 80 | Janssen-Cilag International NVINDUSTRY | 11 | Feb 17, 2017 | clinicaltrials |
| NCT02435108 | A Pilot Study of Crizotinib in Patients With c-MET Positive Gastric Adenocarcinoma as a Third-line Chemotherapy | completed | Phase 2 | 2 | Samsung Medical CenterOTHER | 1 | Feb 17, 2017 | clinicaltrials |
| NCT03054883 | Observational Study for Patients With Newly Diagnosed (MCL) Not Eligible for High-dose Therapy | completed | — | 73 | Czech Lymphoma Study GroupOTHER | 0 | Feb 16, 2017 | clinicaltrials |
| NCT01475058 | CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant | completed | Phase 1 / Phase 2 | 1 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 15, 2017 | clinicaltrials |
| NCT00460694 | Allogeneic Cytokine-induced Killer Immunotherapy for Relapse After Allogeneic Marrow Transplant for Haematological Malignancies(alloCIK) | completed | Phase 1 / Phase 2 | 24 | Singapore General HospitalOTHER | 1 | Feb 10, 2017 | clinicaltrials |
| NCT01300026 | AMG 319 Lymphoid Malignancy FIH | completed | Phase 1 | 28 | AmgenINDUSTRY | 1 | Feb 9, 2017 | clinicaltrials |
| NCT00143065 | Fludarabine, Rituximab, and Alemtuzumab for B-Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 2 | 8 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Feb 8, 2017 | clinicaltrials |
| NCT00201682 | Etanercept and Rituximab in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma | completed | Phase 1 / Phase 2 | 36 | John ByrdOTHER | 1 | Feb 8, 2017 | clinicaltrials |
| NCT00790647 | Melphalan, Bortezomib, and Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis | completed | Phase 2 | 10 | Boston Medical CenterOTHER | 1 | Feb 6, 2017 | clinicaltrials |
| NCT01852591 | Exploration of Immune Response to Early PCV13 Vaccination in Conjunction With Autologous Transplant(PCV13) | completed | N/A | 8 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Feb 2, 2017 | clinicaltrials |
| NCT00633594 | Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma | completed | Phase 1 / Phase 2 | 39 | SCRI Development Innovations, LLCOTHER | 1 | Jan 31, 2017 | clinicaltrials |
| NCT03037177 | Mediastinal Grey Zone Lymphoma From the LYSA | completed | — | 99 | Hospices Civils de LyonOTHER | 1 | Jan 31, 2017 | clinicaltrials |
| NCT01029054 | Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma | completed | Phase 1 / Phase 2 | 53 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jan 30, 2017 | clinicaltrials |
| NCT02341781 | Observational Study of Lenalidomide in Subjects With Mantle Cell Lymphoma Who Failed Ibrutinib Treatment(MCL-004) | completed | — | 30 | CelgeneINDUSTRY | 4 | Jan 26, 2017 | clinicaltrials |
| NCT02169180 | Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma | completed | Phase 2 | 16 | Janssen Pharmaceutical K.K.INDUSTRY | 1 | Jan 24, 2017 | clinicaltrials |
| NCT02953808 | Phase 1 Study of GSK2315698 in Healthy Japanese Subjects | completed | Phase 1 | 18 | GlaxoSmithKlineINDUSTRY | 1 | Jan 19, 2017 | clinicaltrials |
| NCT02452099 | Impact of DMSO Concentrations on Hematopoietic Recovery After Autologous HSC Transplantation.(DMSOconc3) | completed | N/A | 150 | Maria Sklodowska-Curie National Research Institute of OncologyOTHER | 1 | Jan 18, 2017 | clinicaltrials |
| NCT00405756 | A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older. | completed | Phase 3 | 459 | Celgene CorporationINDUSTRY | 22 | Jan 11, 2017 | clinicaltrials |
| NCT00477035 | Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies | completed | Phase 1 | 22 | Sally AraiOTHER | 1 | Jan 11, 2017 | clinicaltrials |
| NCT00931918 | Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients | completed | Phase 2 | 206 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Jan 11, 2017 | clinicaltrials |
| NCT01741792 | Clinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) | completed | Phase 2 | 25 | Amgen Research (Munich) GmbHINDUSTRY | 1 | Jan 6, 2017 | clinicaltrials |
| NCT00099047 | Celecoxib in Preventing Multiple Myeloma in Patients With Monoclonal Gammopathy or Smoldering Myeloma | completed | Phase 2 | 23 | National Cancer Institute (NCI)NIH | 1 | Dec 30, 2016 | clinicaltrials |
| NCT02997813 | Assessment of Mobilization Cost for Multiple Myeloma Using 2 Different Mobilization Strategies(MOZOBIL) | completed | — | 112 | Intergroupe Francophone du MyelomeNETWORK | 1 | Dec 20, 2016 | clinicaltrials |
| NCT02992223 | Retrospective Analysis on Relapsed/Refractory Aggressive Non Hodgkin Lymphoma Treated With Z-BEAM Plus ASCT | completed | — | 58 | A.O.U. Città della Salute e della ScienzaOTHER | 0 | Dec 14, 2016 | clinicaltrials |
| NCT00040937 | S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma | completed | Phase 2 | 147 | SWOG Cancer Research NetworkNETWORK | 1 | Dec 8, 2016 | clinicaltrials |
| NCT00306735 | Safety and Efficacy Study for the Prevention of Nausea and Vomiting in Multiple Myeloma Patients Receiving Stem Cell Transplantation. | completed | Phase 2 | 75 | Eisai Inc.INDUSTRY | 1 | Dec 5, 2016 | clinicaltrials |
| NCT01880762 | Evaluation of PET/MR and PET/CT Imaging for Bone Marrow Lesions | completed | — | 44 | NYU Langone HealthOTHER | 1 | Dec 2, 2016 | clinicaltrials |
| NCT00091624 | A Study of Doxil, Vincristine and Decadron (DVd) +/ CC-5013 in Relapsed Refractory Multiple Myeloma (MM) | completed | Phase 1 | 77 | Celgene CorporationINDUSTRY | 1 | Dec 1, 2016 | clinicaltrials |
| NCT02978898 | CD180 Overexpression in Follicular Lymphoma | completed | — | 184 | Hospices Civils de LyonOTHER | 0 | Dec 1, 2016 | clinicaltrials |
| NCT00378209 | Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma | completed | Phase 2 | 65 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 17, 2016 | clinicaltrials |
| NCT00656084 | Ph2 Gem/Nov/Rituxan Rel/Ref MantleCell | completed | Phase 2 | 16 | US Oncology ResearchINDUSTRY | 0 | Nov 3, 2016 | clinicaltrials |
| NCT00930514 | A Pharmacokinetic Study of Subcutaneous and Intravenous Rituximab in Participants With Follicular Lymphoma | completed | Phase 1 | 281 | Hoffmann-La RocheINDUSTRY | 22 | Nov 2, 2016 | clinicaltrials |
| NCT01122875 | A Study of the Safety and Pharmacokinetics of MFGR1877S in Patients With Relapsed or Refractory t(4;14)-Positive Multiple Myeloma | completed | Phase 1 | 14 | Genentech, Inc.INDUSTRY | 2 | Nov 2, 2016 | clinicaltrials |
| NCT01432353 | A Study of DFRF4539A in Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 39 | Genentech, Inc.INDUSTRY | 1 | Nov 2, 2016 | clinicaltrials |
| NCT01804140 | A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib) | completed | — | 662 | Genentech, Inc.INDUSTRY | 1 | Nov 2, 2016 | clinicaltrials |
| NCT02011113 | Japanese Phase 2 Study to Evaluate the Efficacy and Safety of Pomalidomide in Subjects With Relapsed and Refractory Multiple Myeloma | completed | Phase 2 | 36 | Celgene CorporationINDUSTRY | 1 | Nov 1, 2016 | clinicaltrials |
Data updated 23 days agoSource updated Mar 9, 2017source: clinicaltrials